- HK$84.10bn
- HK$79.10bn
- CNY3.06bn
Brief: Akeso Announced That Ivonescimab Granted Priority Review Of NDA By China Nmpa
Brief: Akeso Announced NDA Acceptance Of IL-12/IL-23 Monoclonal Antibody Ebdarokimab For Moderate-To-Severe Plaque Psoriasis By China NMPA
Brief: Akeso Says NMPA Accepted New Drug Application For Ebdarokimab Injection
Brief: Akeso Announces First Patient Dosed In Phase 3 Trial Of Ivonescimab Versus Tislelizumab
Brief: Akeso Sees Profit Of Not Less Than Rmb2.3 Billion For Six Months
Brief: Akeso Says NMPA Accepted New Drug Application For Ebronucimab Injection
Brief: Akeso Says Xi Xiaojie Tendered His Resignation As CFO
Brief: Specialised Therapeutics Signs Partnership Agreement With Akeso, CTTQ-Akeso To Commercialise New Anti-PD1 Antibody In Australia And Southeast Asia
China's biopharmaceutical firm Akeso jumps most in 10 weeks on strong annual sales
Brief: Akeso Says Total Comprehensive Loss For Year RMB1.29 Billion
Brief: Akeso Receives First Tranche Of $300 Mln Upfront Payment From Summit As Part Of Deal
Evoqua Water rises on $7.5-bln buyout deal by Xylem
Brief: Summit Therapeutics Closes Deal With Akeso Inc To In-License Bispecific Antibody
Brief: Akeso Says Anniko (Penpulimab) Granted Marketing Approval By National Medical Products Administration
Summit Therapeutics gains on up to $5 bln licensing deal for cancer therapy
Summit Therapeutics in up to $5 bln licensing deal for Akeso's cancer therapy (updated)
Brief: Akeso Inc Announces Collaboration, License Agreement For Up To US $5 Bln With Summit Therapeutics
Brief: Summit Therapeutics Partners With Akeso Inc In Deal For Up To $5 Bln
Summit Therapeutics signs up to $5 bln licensing deal for experimental cancer therapy